Sildenafil & Retinal Detachment Risk in Men with ED – Study Finds Link

The popular medication sildenafil, commonly known by the brand name Viagra, is now linked to a heightened risk of a specific eye condition called serous retinal detachment, according to a newly published study. This finding adds to a growing body of evidence suggesting potential ocular side effects associated with phosphodiesterase type 5 inhibitors (PDE5is), a class of drugs primarily used to treat erectile dysfunction.

Understanding Serous Retinal Detachment

Serous retinal detachment isn’t the same as a typical retinal detachment requiring immediate surgical repair. It involves a buildup of fluid under the retina, causing it to separate from the underlying tissue. Whereas it doesn’t always cause immediate vision loss, it can lead to distorted vision and, if left untreated, potentially more serious complications. The condition is relatively rare, making the observed association with sildenafil particularly noteworthy.

The research, published in Scientific Reports on February 21, 2026, utilized data from the TriNetX US collaborative network, a large database of de-identified electronic health records. Researchers analyzed data from over 129 million patients across more than 70 health systems. The study focused on men diagnosed with erectile dysfunction, comparing those who used sildenafil to those who did not.

Study Design and Key Findings

Researchers included men aged 18 years or older with an ICD-10 diagnosis of erectile dysfunction (N52). Exposure was defined as documented sildenafil use (RxNorm 136411). A control group consisted of men with erectile dysfunction who had no recorded sildenafil exposure. Crucially, the study excluded individuals with a prior history of serous retinal detachment, retinal vascular occlusion (RVO), ischemic optic neuropathy (ION), other ocular diseases, or exposure to other PDE5 inhibitors like tadalafil, avanafil, and vardenafil. This careful exclusion process aimed to isolate the potential effect of sildenafil itself.

The study employed a retrospective cohort design, meaning it looked back at existing data to identify patterns. While this approach can reveal associations, it cannot definitively prove cause and effect. The researchers used propensity score matching to account for potential differences between the sildenafil and control groups, attempting to create comparable cohorts. The findings indicated an increased risk of serous retinal detachment among sildenafil users, though the specific risk ratio wasn’t detailed in the initial Medscape report. Further details regarding the magnitude of the risk are available through subscription access to the full study.

Beyond Sildenafil: The Broader Picture of PDE5 Inhibitors and Eye Health

This isn’t the first time a link between PDE5 inhibitors and eye problems has been suggested. A 2022 study published in JAMA Ophthalmology, cited in the Scientific Reports paper, found associations between PDE5 inhibitor use and increased risks of serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy. That study, involving a large observational cohort of older US men, reinforced concerns about potential ocular adverse events.

Retinal vascular occlusion (RVO) involves a blockage of the blood vessels in the retina, potentially leading to vision loss. Ischemic optic neuropathy (ION) affects the optic nerve, which transmits visual information from the eye to the brain, and can also cause sudden vision loss. The mechanisms underlying these potential associations are not fully understood, but researchers hypothesize that PDE5 inhibitors may affect blood flow regulation in the eye.

What Does This Mean for Patients?

It’s important to emphasize that the study demonstrates an association, not necessarily a direct causal link. Many men use sildenafil without experiencing any eye problems. While, individuals taking sildenafil, particularly those with pre-existing eye conditions or risk factors, should be aware of this potential association. Any latest visual disturbances, such as blurred vision, distorted vision, or floaters, should be promptly reported to a qualified eye care professional.

The study’s findings do not warrant immediate discontinuation of sildenafil for all users. However, open communication with a healthcare provider is crucial. Patients can discuss their individual risk factors and weigh the potential benefits of sildenafil against the potential risks.

Limitations and Future Research

The retrospective nature of the study is a key limitation. Retrospective studies are susceptible to confounding factors – variables that can influence the results but are not accounted for in the analysis. For example, underlying health conditions or lifestyle factors could contribute to both sildenafil use and the development of serous retinal detachment.

Further research is needed to confirm these findings and elucidate the underlying mechanisms. Prospective studies, which follow participants over time, would provide stronger evidence of causality. Studies investigating the risk associated with different PDE5 inhibitors and varying dosages are warranted. The researchers note that access to the full study is available through institutional subscriptions or individual purchase on SpringerLink.

Ongoing Surveillance and Guidance Updates

Health authorities are likely to monitor the emerging evidence regarding PDE5 inhibitors and ocular adverse events. The Food and Drug Administration (FDA) may review the available data and consider whether updates to drug labeling or prescribing information are necessary. Similarly, professional organizations such as the American Academy of Ophthalmology may issue guidance to eye care professionals regarding the evaluation and management of patients taking PDE5 inhibitors. Staying informed about official public health updates and recommendations is always advisable.